Events

Rappel de Vancomycin Assay (performed on cobas C and Modular Analytics P-Module)

Selon Department of Health, Therapeutic Goods Administration, ce/cet/cette rappel concerne un dispositif en/au/aux/à Australia qui a été fabriqué par Roche Diagnostics Australia Pty Limited.

Qu'est-ce que c'est?

Une correction ou un retrait opéré par un fabricant afin de répondre à un problème causé par un dispositif médical. Les rappels surviennent lorsqu'un dispositif médical est défectueux, lorsqu'il pourrait poser un risque pour la santé, ou les deux à la fois.

En savoir plus sur les données ici
  • Type d'événement
    Recall
  • ID de l'événement
    RC-2016-RN-00783-1
  • Classe de risque de l'événement
    Class II
  • Date de mise en oeuvre de l'événement
    2016-06-15
  • Pays de l'événement
    Australia
  • Source de l'événement
    DHTGA
  • URL de la source de l'événement
    https://apps.tga.gov.au/Prod/sara/arn-detail.aspx?k=RC-2016-RN-00783-1
  • Notes / Alertes
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notes supplémentaires dans les données
  • Cause
    Previously, roche had received complaints about high recovery of the vancomycin assay in the context of external survey samples. to correct this, a lc-ms/ms reference method for the quantification of vancomycin was developed and released in 2014. as a result of this, updated instrument factors were required to correct possible high recovery and to align the various roche analysers. for the cobas integra system a slight adaptation of the reagent components is required instead of an updated instrument factor. since the cobas integra reagent is not yet adapted, results generated with this reagent are still higher by up to 20% in comparison to the cobas c modules or the modular analytics p-module. the method comparison in the ifu may lead to the assumption that both methods are comparable which may affect the interpretation of vancomycin test results.
  • Action
    Incorrect method comparison will be deleted from the IFUs. Corrected IFU will be provided to all users. In the interim, Roche is advising users to disregard the incorrect method comparison in the Instructions for Use (IFU).

Device

Vancomycin Assay (performed on cobas C and Modular Analytics P-Module)
  • Modèle / numéro de série
    Vancomycin Assay (performed on cobas C and Modular Analytics P-Module)Online TDM Vancomycin Material Number: 04491050190Instrument affected: cobas c 501/502 moduleHitachi VancomycinMaterial Number: 04642481190 Instrument affected: MODULAR ANALYTICS P-MODULEARTG Number: 174910
  • Manufacturer
    Roche Diagnostics Australia Pty Limited

Manufacturer

Roche Diagnostics Australia Pty Limited